Company / Return on Equity (ROE)
NovoCure Ltd Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-40.0%
FY2025
5-year range
-57.1% / -14.2%
FY2021-FY2025
Trend
+14.5%
vs FY2024
Sector context
#134 of 147
Health Care
What the data says
NovoCure Ltd reports negative total equity of -40.0% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-40.0% in FY2025 with a 5-year CAGR of -44.2%.
Improved from -57.1% to -40.0% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -19.0pp
- 5-Year Change
- -44.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 147This company -40.0% Sector average -3.0%
▼
-1215.2% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 14.5% year-over-year.
- Currently 37.0pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -40.0% | +14.5% |
| FY2024 | -46.8% | +18.0% |
| FY2023 | -57.1% | -172.4% |
| FY2022 | -21.0% | -47.6% |
| FY2021 | -14.2% | -441.6% |
| FY2020 | 4.2% | +225.3% |
| FY2019 | -3.3% | +94.1% |
| FY2018 | -56.6% | -4.3% |
| FY2017 | -54.3% | +41.4% |
| FY2016 | -92.6% | -108.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026